Full-Time

Senior Director

Opinion Leader Programming HIV Treatment

Updated on 8/26/2026

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$261.4k - $338.3k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

Foster City, CA, USA

Hybrid

Hybrid work may be available.

Bachelor's, Master's, MBA, PharmD, PhD, MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Marketing

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • A minimum of 14 years of experience with a Bachelor of Science or Bachelor of Arts degree, or 12 years of experience with a Master of Science, Master of Arts, or Master of Business Administration degree.
  • A Bachelor's degree in marketing or a related field is required.
  • Prior people-management experience is required.
  • Ability to set a vision, cultivate a high-performance culture, and lead diverse teams.
  • Ability to tackle complex business problems, make recommendations, and incorporate stakeholder input and feedback.
  • Ability to form and maintain collaborative relationships with external opinion leaders and internal cross-functional partners.
  • Strong interpersonal, verbal communication, and writing skills, including the ability to simplify complex topics.
  • Ability to lead through others and manage highly cross-functional teams or workgroups.
  • Excellence in project management and the ability to manage multiple projects and priorities.
  • Ability to understand and communicate clinical data and high-level science.
  • Ability to drive consensus and manage conflicts among individuals from varied cultures and disciplines.
  • Understanding of pharmaceutical regulatory requirements and their impact on marketing materials.
  • Ability to ensure compliance with relevant laws, regulations, and policies.
Responsibilities
  • Contribute to long- and short-term United States HIV treatment brand strategies and plans of action.
  • Partner with the PrEP opinion leader programming team to ensure synergies across opinion leader engagement.
  • Develop the opinion leader programming strategic and tactical plan.
  • Provide strategic oversight and management of speaker bureaus, advisory boards, conference debriefs, opinion leader mapping and databases, account management, and opinion leader-generated content.
  • Monitor the HIV landscape and identify opportunities to support brand strategies.
  • Translate scientific, clinical, epidemiological, and research insights into actionable commercial ideas and activities.
  • Establish and maintain relationships with key opinion leaders, key accounts, and medical associations.
  • Collaborate with treatment, prevention, and franchise marketing teams, medical teams, and sales leadership to maximize effectiveness.
  • Lead or serve as a key commercial member on high-visibility cross-functional initiatives.
  • Provide innovative thinking, clear communication, and change management.
  • Support navigation of marketing materials through internal review processes to ensure regulatory and legal compliance.
  • Establish procedures, systems, metrics, and infrastructure for the opinion leader programming team.
  • Synthesize the department budget, articulate tradeoffs across brands and priorities, identify risks, and present recommendations or decision points.
  • Design and deliver presentations to internal stakeholders and external audiences.
  • Coach, develop, and manage direct reports.
  • Identify and engage agency partnerships to support opinion leader programming efforts.
  • Create inclusion, develop talent, and empower teams by aligning goals and supporting employee growth and performance.
Desired Qualifications
  • Advanced experience with product lifecycle management.
  • An advanced science degree such as a Doctor of Medicine, Doctor of Pharmacy, or Doctor of Philosophy, or an advanced business degree such as a Master of Business Administration.
  • Extensive knowledge and experience in pharmaceutical product lifecycle management across a variety of therapeutic areas.
  • Biopharmaceutical or pharmaceutical experience.
  • Track record of successful pharmaceutical or biotechnology marketing in specialty categories.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales excluding Veklury rose 10% to $7.6 billion.
  • Management raised 2026 product-sales guidance to $30.1-$30.4 billion after strong HIV demand.
  • FDA accepted Yeztugo tablets and anito-cel, with decisions due February and December 2026.

What critics are saying

  • HIV produced 75% of Q2 2026 product sales, leaving Gilead dangerously concentrated.
  • California Supreme Court killed 23,000-24,000 duty-to-innovate claims, but future drug-liability theories remain.
  • Gilead booked $11.2 billion acquired IPR&D charges; anito-cel failure would crush oncology diversification.

What makes Gilead Sciences unique

  • Gilead dominates HIV, with Biktarvy and Yeztugo driving 2026 growth.
  • Yeztugo's twice-yearly PrEP dosing creates a distinct adherence advantage over daily pills.
  • Arcellx's anito-cel adds late-stage CAR-T exposure beyond HIV and hepatitis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 24th, 2026
Gilead posts $11B loss on pipeline acquisitions despite 10% product sales growth

Gilead Sciences reported strong commercial performance in Q2 2026, with product sales excluding Veklury rising 10% to $7.6 billion. HIV revenue grew 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy at $967 million. Despite this growth, the company posted one of its largest quarterly losses due to over $11 billion in acquired research and development expenses. These acquisitions included Arcellx, which gives Gilead full control of anito-cel, a CAR-T treatment for multiple myeloma pending FDA approval by December 2026. The company raised its 2026 product-sales guidance to $30.1–$30.4 billion. Gilead also reported encouraging progress beyond HIV, with liver-disease revenue up 10% and Trodelvy breast-cancer treatment sales rising 26% to $457 million.

Yahoo Finance
Aug 23rd, 2026
Gilead's HIV sales surge 12% to $5.7B, but franchise accounts for 75% of total revenue

Gilead Sciences reported strong fiscal Q2 2026 results, with total revenue rising 10% year-over-year to approximately $7.8 billion. The growth was primarily driven by its HIV franchise, including Biktarvy and newly launched Yeztugo. HIV product sales rose 12% to $5.7 billion, representing nearly three-quarters of quarterly product sales. Descovy sales increased 48% to $967 million, whilst Biktarvy sales grew 7% to $3.8 billion. Yeztugo generated $232 million, up substantially from $15 million in the prior-year period. The company's liver disease portfolio sales rose 10% to $877 million. However, cell therapy sales declined 14% to $417 million, reflecting competitive pressure. Gilead recorded an $11.2 billion quarterly loss due to acquired research and development expenses, including $7.0 billion for the Arcellx acquisition.

Insider Monkey
Aug 23rd, 2026
Gilead's HIV business is surging, but is the company too dependent on one franchise?

Gilead's HIV business is surging, but is the company too dependent on one franchise? Published on august 23, 2026 at 7:15 pm by noor ul ain rehman in hedge funds, news. Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, including Biktarvy and the newly launched Yeztugo. Gilead also raised its full-year product-sales guidance following the quarter. However, HIV products generated nearly three-quarters of quarterly product sales. While the company's HIV business is showing promising growth, is Gilead Sciences, Inc. (NASDAQ:GILD) too dependent on one franchise? Bull case. One of the most prominent factors supporting higher revenue growth for Gilead (NASDAQ:GILD) was increased sales of its HIV products, Trodelvy(R)(sacituzumab govitecan-hziy) and Livdelzi(R)(seladelpar). HIV product sales rose 12% to $5.7 billion in Q2 2026 compared to the same period in 2025, driven primarily by higher average realized price and demand. Descovy sales rose 48% to $967 million in the quarter compared to the same period in 2025, while Biktarvy sales increased 7% to $3.8 billion. The continued growth shows that Gilead's (NASDAQ:GILD) established HIV business remains healthy rather than relying entirely on new launches. Yeztugo could create another major HIV franchise for the company, as it generated $232 million in Q2, a substantial increase from $15 million in the prior-year period. Yeztugo's early uptake suggests that its twice-yearly dosing could expand Gilead's (NASDAQ:GILD) prevention business rather than merely replace existing products. Nevertheless, it remains too early to determine the treatment's long-term market share. Furthermore, Gilead's (NASDAQ:GILD) liver-disease portfolio demonstrates that growth is not completely confined to HIV, even though these businesses remain considerably smaller. The Liver Disease portfolio sales rose 10% to $877 million in Q2 2026 compared to the prior-year period, primarily reflecting higher demand for Livdelzi, along with chronic hepatitis B virus products and Hepcludex. Bear case. HIV products contributed approximately $5.7 billion of Gilead's (NASDAQ:GILD) roughly $7.6 billion in quarterly product sales, meaning the franchise accounted for approximately three-quarters of total product sales. Strong HIV growth is currently an advantage, but the concentration creates long-term risk if competition, pricing pressure, or changes in prevention and treatment markets weaken the franchise. Trodelvy performed well, but Gilead's (NASDAQ:GILD) cell-therapy sales declined 14% to $417 million in the second quarter of 2026 compared to the same period in 2025, reflecting continued competitive pressure. This shows that the company's broader oncology strategy has not yet produced consistent portfolio-wide growth. Gilead (NASDAQ:GILD) also recorded a substantial quarterly loss of $11.2 billion because of acquired research and development expenses associated with transactions involving $7.0 billion for the Arcellx acquisition, $3.1 billion for the Tubulis acquisition, and $1.0 billion for the Ouro Medicines acquisition, net of the impact of the Lakefront collaboration. These charges do not indicate that Gilead's (NASDAQ:GILD) established products became unprofitable. However, they demonstrate the considerable price the company is paying to build growth outside HIV, while the acquired assets still carry clinical and commercial risk. What do hedge funds think? Hedge fund sentiment provides additional context for Gilead's (NASDAQ:GILD) investment case. According to Insider Monkey's database of 1,022 hedge funds, the number of funds holding the stock increased from 71 in Q4 2025 to 77 in Q1 2026. The increase suggests that institutional sentiment became moderately more constructive, although it does not by itself establish a decisive shift in conviction. Conclusion. Gilead's (NASDAQ:GILD) investment case has strengthened as Biktarvy continues to grow and Yeztugo establishes itself as a potentially important HIV-prevention product. Trodelvy and the liver-disease portfolio provide additional sources of growth, while management's guidance increase signals confidence in the underlying business. However, the company remains heavily dependent on HIV, and its expensive effort to create a more diversified oncology portfolio has yet to demonstrate consistent commercial success. Gilead's (NASDAQ:GILD) near-term outlook appears strong, but its longer-term rerating may depend on proving that it can build another major franchise outside HIV. Disclosure: None. This article is originally published at Insider Monkey. Related Insider Monkey Articles

Ticker Report
Aug 18th, 2026
MidFirst Bank Makes New $810,000 Investment in Gilead Sciences, Inc. $GILD

MidFirst Bank acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,414 shares of the biopharmaceutical company’s stock, valued at approximately $810,000. A number of other hedge funds and other institutional investors […]

Yahoo Finance
Aug 16th, 2026
Gilead Sciences down 11.3% in six months as revenue growth disappoints at 2.7% CAGR

Gilead Sciences' shares have fallen 11.3% to $137.77 over the past six months, contrasting with the S&P 500's 13.1% gain. The biopharmaceutical company has shown disappointing long-term performance, with revenue growing at just 2.7% annually over five years. The company's profitability metrics have deteriorated significantly. Its adjusted operating margin decreased by 34.2 percentage points over the past five years, landing at 9.7% for the trailing 12 months. Earnings per share declined by 15.4% annually during the same period, indicating reduced profitability as the company expanded. Despite trading at a relatively fair valuation of 14.9× forward price-to-earnings ratio, analysts suggest limited upside potential compared to downside risk.